The Pediatric Oncology Group (POG) is composed of 41 institutions, 36 affiliate or consortial institutions and 7 CCOPs who have pooled their patient resources and scientific expertise to study the natural history of childhood cancer, to develop effective therapeutic regimens and to develop clinical trials of new therapeutic agents in children with cancer. There are 1,103 member investigators which includes pediatric oncologists, pathologists, surgeons, radiation therapists, radiologists, epidemiologists, neurologists, cytogeneticists, immunologists, pharmacologists, psychiatrists and statisticians. Reference laboratories for immunophenotyping, cytogenetics, DNA ploidy, molecular genetics, CML, and pathology are established at various member institutions to further basic changes in malignant cells and tumor growth and for quality control. Additionally pharmacology studies on phase I and the front line ALL studies are ongoing. The Group Chairman provides executive and scientific guidance and is responsible for creating an environment which will encourage the development of research protocols of the highest scientific merit. The Pediatric Oncology Group Operations Office provides the staff and serves as the central office for collection, processing, classification and distribution of information that is necessary for member investigators to participate in the research activities of the Group. This office prepares, edits, processes and distributes POG protocols from the initial concept to activation and provides amendments and revisions as necessary. The staff will also help the Disease Committee Chairman track manuscripts until their publication. It is responsible for arranging, conducting and supervising POG meetings and generating and distributing minutes of these. meetings. This office arranges and coordinates quality control and institutional audits. All of the activity of the Operations Office is coordinated with that of the Statistical Office. This application is requesting continued funding for the POG Operations Office and includes budgets for standing committees, major coordinators and reference laboratories.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
7U10CA030969-14
Application #
3557148
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1993-07-01
Project End
1995-12-31
Budget Start
1993-07-01
Budget End
1993-12-31
Support Year
14
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Tower, Richard L; Jones, Tamekia L; Camitta, Bruce M et al. (2014) Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group. J Pediatr Hematol Oncol 36:353-61
Mansour, Marc R; Abraham, Brian J; Anders, Lars et al. (2014) Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346:1373-7
Duffner, Patricia K; Armstrong, Floyd Daniel; Chen, Lu et al. (2014) Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence? A rep J Pediatr Hematol Oncol 36:8-15
Lupo, Philip J; Zhou, Renke; Skapek, Stephen X et al. (2014) Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: a report from the Children's Oncology Group. Int J Cancer 134:431-6
Lupo, Philip J; Danysh, Heather E; Skapek, Stephen X et al. (2014) Maternal and birth characteristics and childhood rhabdomyosarcoma: a report from the Children's Oncology Group. Cancer Causes Control 25:905-13
Kelly, Katherine P; Hooke, Mary C; Ruccione, Kathleen et al. (2014) Children's Oncology Group nursing research framework. Semin Oncol Nurs 30:17-25
Kreissman, Susan G; Seeger, Robert C; Matthay, Katherine K et al. (2013) Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 14:999-1008
Kelly, Michael E; Lu, Xiaomin; Devidas, Meenakshi et al. (2013) Treatment of relapsed precursor-B acute lymphoblastic leukemia with intensive chemotherapy: POG (Pediatric Oncology Group) study 9411 (SIMAL 9). J Pediatr Hematol Oncol 35:509-13
Schrappe, Martin; Hunger, Stephen P; Pui, Ching-Hon et al. (2012) Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 366:1371-81
Caniza, Miguela A; Hunger, Stephen P; Schrauder, Andre et al. (2012) The controversy of varicella vaccination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 58:12-6

Showing the most recent 10 out of 198 publications